ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Short burst of radiation before Immuno-Chemo may boost esophageal cancer response
Disease control Not yet recruitingThis study tests whether a short course of radiation followed by the immunotherapy drug tislelizumab plus chemotherapy can improve outcomes for people with a type of esophageal cancer that can be surgically removed. About 50 participants will receive either a low or high dose of …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New hope for tough esophageal cancer: HS-20093 enters final trial
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will rece…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study tests whether a short course of radiation followed by three cycles of the immunotherapy drug serplulimab plus chemotherapy can help shrink esophageal tumors before surgery. It includes 22 adults with resectable esophageal squamous cell carcinoma. The goal is to see if …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Immunotherapy combo shows promise in battling esophageal cancer before surgery
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with resectable locally advanced esophageal squamous cell carcinoma. About 390 participants will be randomly assigned to receive either torip…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Glowing dye could seal esophageal surgery leaks
Disease control Not yet recruitingThis study tests a new surgical technique for people with esophageal cancer. The method uses a special dye to check blood flow and wraps the surgical connection with a piece of belly tissue to prevent leaks. About 73 adults will receive this procedure to see if it lowers the risk…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New protocol aims to plug deadly hole in esophageal cancer care
Disease control Not yet recruitingThis study tests a standardized care plan for esophageal fistula, a severe complication of advanced esophageal cancer where a hole forms between the esophagus and windpipe or chest. The plan includes sealing the hole with stents, antibiotics, nutrition support, and further cancer…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for tough esophageal cancers: triple therapy shows promise
Disease control Not yet recruitingThis study is for people with esophageal cancer that did not shrink after initial treatment. It tests whether adding low-dose radiation to a combination of immunotherapy (toripalimab) and chemotherapy can improve outcomes. Participants will receive the treatment before surgery, a…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug may help keep esophageal cancer at bay after standard treatment
Disease control Not yet recruitingThis Phase 3 trial tests whether the immunotherapy drug toripalimab can help prevent cancer from growing in people with advanced esophageal cancer who have already received chemotherapy and radiation. About 340 participants will be randomly assigned to receive toripalimab or just…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New study aims to decode esophageal Cancer's secrets
Knowledge-focused Not yet recruitingThis study will follow 255 people with esophageal cancer to understand how the disease changes over time. Researchers will use advanced tests like genetic analysis, imaging, and immune profiling. The goal is to improve how doctors predict cancer progression and response to treatm…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: Peking University Cancer Hospital & Institute • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:50 UTC